These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 32274652)
81. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Jenkins V; Shilling V; Deutsch G; Bloomfield D; Morris R; Allan S; Bishop H; Hodson N; Mitra S; Sadler G; Shah E; Stein R; Whitehead S; Winstanley J Br J Cancer; 2006 Mar; 94(6):828-34. PubMed ID: 16523200 [TBL] [Abstract][Full Text] [Related]
82. Long-term cognitive impairment of breast cancer patients after chemotherapy: A functional MRI study. Miao H; Li J; Hu S; He X; Partridge SC; Ren J; Bian Y; Yu Y; Qiu B Eur J Radiol; 2016 Jun; 85(6):1053-7. PubMed ID: 27161051 [TBL] [Abstract][Full Text] [Related]
83. Selective impairment of attention networks in breast cancer patients receiving chemotherapy treatment. Chen X; Li J; Ren J; Hu X; Zhu C; Tian Y; Hu P; Ma H; Yu F; Wang K Psychooncology; 2014 Oct; 23(10):1165-71. PubMed ID: 24737580 [TBL] [Abstract][Full Text] [Related]
84. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Stewart A; Bielajew C; Collins B; Parkinson M; Tomiak E Clin Neuropsychol; 2006 Feb; 20(1):76-89. PubMed ID: 16410227 [TBL] [Abstract][Full Text] [Related]
85. Executive functioning impairment in women treated with chemotherapy for breast cancer: a systematic review. Yao C; Bernstein LJ; Rich JB Breast Cancer Res Treat; 2017 Nov; 166(1):15-28. PubMed ID: 28707202 [TBL] [Abstract][Full Text] [Related]
86. Brain vulnerability to chemotherapy toxicities. Ahles TA Psychooncology; 2012 Nov; 21(11):1141-8. PubMed ID: 23023994 [TBL] [Abstract][Full Text] [Related]
87. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. van Dam FS; Schagen SB; Muller MJ; Boogerd W; vd Wall E; Droogleever Fortuyn ME; Rodenhuis S J Natl Cancer Inst; 1998 Feb; 90(3):210-8. PubMed ID: 9462678 [TBL] [Abstract][Full Text] [Related]
88. Prechemotherapy Levels of Plasma Dehydroepiandrosterone and Its Sulfated Form as Predictors of Cancer-Related Cognitive Impairment in Patients with Breast Cancer Receiving Chemotherapy. Toh YL; Shariq Mujtaba J; Bansal S; Yeo A; Shwe M; Lau AJ; Chan A Pharmacotherapy; 2019 May; 39(5):553-563. PubMed ID: 30892712 [TBL] [Abstract][Full Text] [Related]
89. Chemotherapy-related cognitive impairment: mechanisms, clinical features and research perspectives. Cascella M; Di Napoli R; Carbone D; Cuomo GF; Bimonte S; Muzio MR Recenti Prog Med; 2018 Nov; 109(11):523-530. PubMed ID: 30565571 [TBL] [Abstract][Full Text] [Related]
90. Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Askren MK; Jung M; Berman MG; Zhang M; Therrien B; Peltier S; Ossher L; Hayes DF; Reuter-Lorenz PA; Cimprich B Breast Cancer Res Treat; 2014 Sep; 147(2):445-55. PubMed ID: 25138546 [TBL] [Abstract][Full Text] [Related]
91. Cognitive impairment after cytotoxic chemotherapy. Huehnchen P; van Kampen A; Boehmerle W; Endres M Neurooncol Pract; 2020 Jan; 7(1):11-21. PubMed ID: 32257280 [TBL] [Abstract][Full Text] [Related]
92. Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. Lee PE; Tierney MC; Wu W; Pritchard KI; Rochon PA Breast Cancer Res Treat; 2016 Aug; 158(3):407-20. PubMed ID: 27432418 [TBL] [Abstract][Full Text] [Related]
93. Neurocognitive effects of chemotherapy and endocrine therapies in the treatment of breast cancer: recent perspectives. Walker CH; Drew BA; Antoon JW; Kalueff AV; Beckman BS Cancer Invest; 2012 Feb; 30(2):135-48. PubMed ID: 22250588 [TBL] [Abstract][Full Text] [Related]
94. Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study. Underwood EA; Jerzak KJ; Lebovic G; Rochon PA; Elser C; Pritchard KI; Tierney MC Support Care Cancer; 2019 Aug; 27(8):3035-3043. PubMed ID: 30610433 [TBL] [Abstract][Full Text] [Related]
95. Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study. Janelsins MC; Heckler CE; Peppone LJ; Ahles TA; Mohile SG; Mustian KM; Palesh O; O'Mara AM; Minasian LM; Williams AM; Magnuson A; Geer J; Dakhil SR; Hopkins JO; Morrow GR J Clin Oncol; 2018 Sep; 36(32):JCO2018786624. PubMed ID: 30240328 [TBL] [Abstract][Full Text] [Related]
96. Patient-reported cognitive impairments and objective neuropsychological deficits in young sarcoma patients undergoing chemotherapy and its comparison to healthy controls: A tertiary health care study from India. Vayyat S; Revand R; Rastogi S; Sharma R; Kaur S Int J Cancer; 2024 Apr; 154(8):1413-1422. PubMed ID: 38088458 [TBL] [Abstract][Full Text] [Related]
97. Cognitive Function in Patients at Different Stages of Treatment for Colorectal Cancer: A Comparative Cross-Sectional Study. Yang HY; Chang YL; Lin BR; Chou YJ; Shun SC Semin Oncol Nurs; 2023 Aug; 39(4):151446. PubMed ID: 37183103 [TBL] [Abstract][Full Text] [Related]
98. [Chemotherapy-induced cognitive impairment in breast cancer patients-risk factors and therapy]. Duma MN Strahlenther Onkol; 2022 Jul; 198(7):667-669. PubMed ID: 35482033 [No Abstract] [Full Text] [Related]
100. Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients. Wu LM; Amidi A Curr Opin Support Palliat Care; 2017 Mar; 11(1):38-45. PubMed ID: 27926544 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]